Bruno Vergès
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bruno Vergès has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Marie Le Bon
Centre des Sciences du Goût et de l'Alimentation, CNRS, INRAE, Institut Agro, Université Bourgogne Franche-Comté, F-21000 Dijon, France
1 shared publication - Chloé Buch
Equipe Physiopathologie des dyslipidémies, Unité Mixte de Recherche Université de Bourgogne Franche-Comté - Institut National de la Santé et de la Recherche Médicale (UMR-INSERM) 1231, F-21000 Dijon, France
1 shared publication - Christine Belloir
Université Bourgogne Europe, Institut Agro, CNRS, INRAE, UMR CSGA, 21000 Dijon, France
1 shared publication - Jean-Michel H. Robert
Nantes Université, Cibles et Médicaments des Infections et de l’Immunité, IICiMed, UR 1155, F-44000 Nantes, France
1 shared publication - Jean-Paul Pais de Barros
Université de Bourgogne Franche-Comté, 21000 Dijon, France
1 shared publication - Julia Leemput
Université Bourgogne Europe, Inserm UMR1231 Center for Translational and Molecular Medicine (CTM), Team Pathophysiology of Dyslipidemia (PADYS), Dijon, France
1 shared publication
Latest Publications
- Open Access
- 20 March 2026
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 87 (3) , 102524
Genetic dyslipidemias
- 20 March 2026
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 87 (3) , 102524
Open AccessGenetic dyslipidemias
- Open Access
- 8 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 2923
Chemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist
Targeting cannabinoid 1 receptors (CB1R) with peripherally restricted antagonists (or inverse agonists) shows promise to improve metabolic disorders associated with obesity. In this context, we designed and synthetized JM-00266, a new CB1R blocker with limited blood–brain barrier (BBB) permeability. Pharmacokinetics were tested with SwissADME and in vivo in rodents after oral and intraperitoneal administration of JM-00266 in comparison with Rimonabant. In silico predictions indicated JM-00266 is a non-brain penetrant compound and this was confirmed by brain/plasma ratios and brain uptake index values. JM-00266 had no impact on food intake, anxiety-related behavior and body temperature suggesting an absence of central activity. cAMP assays performed in CB1R-transfected HEK293T/17 cells showed that the drug exhibited inverse agonist activity on CB1R. In addition, JM-00266 counteracted anandamide-induced gastroparesis indicating substantial peripheral activity. Acute administration of JM-00266 also improved glucose tolerance and insulin sensitivity in wild-type mice, but not in CB1R−/− mice. Furthermore, the accumulation of JM-00266 in adipose tissue was associated with an increase in lipolysis. In conclusion, JM-00266 or derivatives can be predicted as a new candidate for modulating peripheral endocannabinoid activity and improving obesity-related metabolic disorders.
- 8 March 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (6) , 2923
Open AccessChemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist
Targeting cannabinoid 1 receptors (CB1R) with peripherally restricted antagonists (or inverse agonists) shows promise to improve metabolic disorders associated with obesity. In this context, we designed and synthetized JM-00266, a new CB1R blocker with limited blood–brain barrier (BBB) permeability. Pharmacokinetics were tested with SwissADME and in vivo in rodents after oral and intraperitoneal administration of JM-00266 in comparison with Rimonabant. In silico predictions indicated JM-00266 is a non-brain penetrant compound and this was confirmed by brain/plasma ratios and brain uptake index values. JM-00266 had no impact on food intake, anxiety-related behavior and body temperature suggesting an absence of central activity. cAMP assays performed in CB1R-transfected HEK293T/17 cells showed that the drug exhibited inverse agonist activity on CB1R. In addition, JM-00266 counteracted anandamide-induced gastroparesis indicating substantial peripheral activity. Acute administration of JM-00266 also improved glucose tolerance and insulin sensitivity in wild-type mice, but not in CB1R−/− mice. Furthermore, the accumulation of JM-00266 in adipose tissue was associated with an increase in lipolysis. In conclusion, JM-00266 or derivatives can be predicted as a new candidate for modulating peripheral endocannabinoid activity and improving obesity-related metabolic disorders.